SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by D'Cruz, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D'Cruz, D
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Antimalarial therapy: a panacea for mild lupus?

D D'Cruz

The Lupus Research Unit, St Thomas' Hospital, London, SE1 7EH, UK,Tel: +44 207 928 9292 Ext 2710; Fax: +44 207 620 2658

Antimalarial therapy has a long and successful track record in the management of patirents with mild SLE. Medium to long term use of hydroxychloroquine, alone or in combination with mepacrine, ameliorates lupus and may reduce the relapse rate. Recent guidelines for monitoring hydroxychloroquine have reduced the need for frequent visual checks. Antimalarials have other beneficial effects on lipid and glucose metabolism as well as having weak anticoagulant activity. They should be considered for most patients with mild lupus.

Key Words: antimalarials • systemic lupus erythematosus • lipids • thrombosis • glucose metabolism

Lupus, Vol. 10, No. 3, 148-151 (2001)
DOI: 10.1191/096120301669779293


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
LupusHome page
I Cavazzana, R Sala, C Bazzani, A Ceribelli, C Zane, R Cattaneo, A Tincani, P. Calzavara-Pinton, and F Franceschini
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine
Lupus, July 1, 2009; 18(8): 735 - 739.
[Abstract] [PDF]


Home page
J Am Board Fam MedHome page
S. Panjwani
Early Diagnosis and Treatment of Discoid Lupus Erythematosus
J Am Board Fam Med, March 1, 2009; 22(2): 206 - 213.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
J. James, X. Kim-Howard, B. Bruner, M. Jonsson, M. McClain, M. Arbuckle, C. Walker, G. Dennis, J. Merrill, and J. Harley
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus
Lupus, June 1, 2007; 16(6): 401 - 409.
[Abstract] [PDF]


Home page
LupusHome page
A Wozniacka, A Lesiak, J Narbutt, J Kobos, S Pavel, and A Sysa-Jedrzejowska
Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus
Lupus, February 1, 2007; 16(2): 89 - 94.
[Abstract] [PDF]


Home page
LupusHome page
C C Mok and C S Lau
Lupus in Hong Kong Chinese
Lupus, September 1, 2003; 12(9): 717 - 722.
[Abstract] [PDF]


Home page
LupusHome page
A Wozniacka, A Carter, and D P Mccauliffe
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Lupus, February 1, 2002; 11(2): 71 - 81.
[Abstract] [PDF]



Advertisement